HPR supports your R&D activities through:

  • Development and characterization of your NHP disease models

  • Preclinical evaluation of potential therapeutic candidates prior to clinical trials

  • AAALAC International standards for animal care

Our Team

Hiroyuki Takamatsu, Ph.D., CEO

CEO Message:

"Our clients are extremely satisfied with our contract studies, which were completed successfully by our technicians who are highly skilled in handling of nonhuman primates as well as rodents. In addition to our osteoarthritis, pain, and stroke models, HPR recently developed the photochemically-induced thrombosis (PIT) method to induce vascular cyclic flow reduction, a phenomenon observed in vascular thrombosis and cerebral ischemia. HPR integrated PIT with in vivo imaging technologies, including MRI and PET, to track disease progression in the same subject over time. We are fully committed to supporting your drug discovery efforts with professionalism and our extensive experiences and skill sets."

Our History

2005

2010

2013

2015

2016

Founding of Hamamatsu Pharma Research, Inc in Japan
Main office / Central Research Facility established
Primate Center established
Accreditation by AAALAC International
Hamamatsu Pharma Research U.S.A., Inc. established

Our Facilities

  • All studies are reviewed and approved by the Hamamatsu Pharma Research Animal Care and Use Committee.

  • Animal care and housing in accordance with the "Guide for Care ad Use of Laboratory Animals" (Institute for Laboratory Animal Research, 2011) 

  • Our primate center and central research facility are located in Hamamatsu, Japan.

Primate Center

  • 8 holding rooms (up to 300 macaques)

  • 4 procedure rooms

Central Research Facility

  • 3 holding rooms

  • 4 procedure rooms

Follow us:

HPR's AAALAC
HPR ProudCROMember_Biocom

Copyright © HAMAMATSU PHARMA RESEARCH U.S.A., Inc All rights reserved.

Hamamatsu Pharma Research U.S.A., Inc

3070 Bristol Street, Suite 400 Costa Mesa, CA 92626

E-mail: info_us@hpharma.jp

AAALAC